Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;55(5):3916-3930.
doi: 10.1007/s12035-017-0624-1. Epub 2017 May 26.

Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC

Affiliations

Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC

Kazunori Sano et al. Mol Neurobiol. 2018 May.

Abstract

The prion-like seeding of misfolded α-synuclein (αSyn) involved in the pathogenesis of Lewy body diseases (LBD) remains poorly understood at the molecular level. Using the real-time quaking-induced conversion (RT-QUIC) seeding assay, we investigated whether brain tissues from cases of dementia with Lewy bodies (DLB), which contain serine 129 (Ser129)-phosphorylated insoluble aggregates of αSyn, can convert Escherichia coli-derived recombinant αSyn (r-αSyn) to fibrils. Diffuse neocortical DLB yielded 50% seeding dose (SD50) values of 107~1010/g brain. Limbic DLB was estimated to have an SD50 value of ~105/g brain. Furthermore, RT-QUIC assay discriminated DLB from other neurological and neurodegenerative disorders. Unexpectedly, the prion-like seeding was reconstructed in reactions seeded with oligomer-like species, but not with insoluble aggregates of r-αSyn, regardless of Ser129 phosphorylation status. Our findings suggest that RT-QUIC using r-αSyn can be applied to detect seeding activity in LBD, and the culprit that causes prion-like seeding may be oligomeric forms of αSyn.

Keywords: Dementia with Lewy bodies (DLB); Prion; Real-time quaking-induced conversion (RT-QUIC); α-synuclein.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Purification and structural analysis of recombinant α-synuclein. a, b The purified His-tagged recombinant human αSyn (His-r-αSyn), His-r-αSyn after treatment with DAPase (His-r-αSyn + DAPase), and the product after removal of His-r-αSyn and DAPase (r-αSyn) were examined by Coomassie brilliant blue (CBB)-stained SDS-PAGE and western blotting analysis with polyclonal anti-αSyn antibody D119 and anti-His antibody. a CBB-stained SDS-PAGE analysis showed that the size of His-r-αSyn was shifted from 18 to 17 kDa after treatment with DAPase, and a single major band of the protein was observed after removal of His-r-αSyn and DAPase. b A similar shift in molecular size of His-r-αSyn was also observed by immunoblotting using polyclonal anti-αSyn antibody D119. The purified r-αSyn was confirmed not to be detected by immunoblotting using anti-His-tag antibody. Molecular mass markers are indicated in kilodaltons (kDa) on the left side of each panel. c, d r-αSyn was loaded onto 4% – 16% Bis-Tris native PAGE gels (Invitrogen) and separated by BN-PAGE. c CBB-stained BN-PAGE and d western blotting analysis with polyclonal anti-αSyn antibody D119 revealed a native αSyn band at approximately 60 kDa, suggesting a tetramer (theoretical mass of monomer  =  14,460.1 Da). e Circular dichroism (CD) spectrum of r-αSyn showed a minimum mean residue ellipticity at 199 nm, characteristic of disordered protein. f Fourier transform infrared spectroscopy (FTIR) spectrum of r-αSyn. The FTIR spectrum showed a prominent band at 1650 cm−1 assigned to a disordered structure
Fig. 2
Fig. 2
Characterization of α-synuclein from human brains by histochemical and western blotting analysis. a Hematoxylin and eosin staining and immunohistochemical staining using an antibody against phosphorylated αSyn in the substantia nigra and the cortex of the frontal lobe from two patients with DN-DLB (cases #1 and #2), a patient with Li-DLB, and non-DLB case (breast cancer patient). The arrows and arrowheads show LB and pSer129-αSyn, respectively. Scale bar, 50 mm. b, c, d The samples of BH from DN-DLB (cases #1 and #2), Li-DLB, schizophrenia, Alzheimer’s disease (AD) (cases #1 and #2), sporadic Creutzfeldt–Jakob disease (sCJD) type 1 (sCJD MM1) (case #1 and #2), sCJD type 2 (sCJD MM2), and Gerstmann–Sträussler–Scheinker syndrome (GSS) patients were immunoblotted with b polyclonal anti-αSyn antibody D119, c monoclonal anti-pSer129-αSyn antibody, and d polyclonal anti-Ser87-phosphorylated αSyn antibody. In the immunoblotting analysis for pSer129-αSyn presented in c, the samples were detected at a short exposure time of 30 s (upper panel) and long exposure time of 2 min (lower panel). Molecular mass markers are indicated in kilodaltons (kDa) on the left side of each panel. The arrows indicate the top of the stacking gel
Fig. 3
Fig. 3
Fibril formation of r-αSyn in RT-QUIC reactions. a RT-QUIC was performed using human r-αSyn with the indicated dilutions of BH from DN-DLB (cases #1 and #2), Li-DLB, schizophrenia (Sc), AD (cases #1 and #2), sCJD MM1 (cases #1 and #2), sCJD MM2, and GSS patients, or without seed (no-seeded). The colored curves represent the kinetics of ThT fluorescence average of all six replicate wells. See also Supplementary Fig. S3. b The values of maximal fluorescence intensities and lag phase obtained in individual samples after 96-h reaction are plotted in the upper and lower graphs, respectively. Lag phase was defined as the time required to reach a fluorescence intensity > 120 arbitrary units. The horizontal bars indicate means  ±  standard deviation. The data for maximal fluorescence intensities were analyzed by one-way ANOVA, followed by the Tukey–Kramer test. Analysis of the data for lag phase was performed by the log-rank and Tukey–Kramer tests. **P  <  0.01 (compared with no-seeded); *P  <  0.05 (compared with no-seeded)
Fig. 4
Fig. 4
Western blotting and RT-QUIC analysis of another four DN-DLB brains. a The samples of BH from DN-DLB patients (cases #3, #4, #5 and #6) were immunoblotted with polyclonal anti-αSyn antibody D119 and monoclonal anti-pSer129-αSyn antibody. Molecular mass markers are indicated in kilodaltons (kDa) on the left side of each panel. The arrows indicate the top of the stacking gel. b RT-QUIC was performed using human r-αSyn with the indicated dilutions of BH from DN-DLB. The colored curves represent the kinetics of ThT fluorescence average of all six replicate wells. See also Supplementary Fig. S4. c The values of maximal fluorescence intensities and lag phase obtained in individual samples after 96-h reaction are plotted in the upper and lower graphs, respectively. Lag phase was defined as the time required to reach a fluorescence intensity > 120 arbitrary units. The horizontal bars indicate means  ±  standard deviation. The data for maximal fluorescence intensities were analyzed by one-way ANOVA, followed by the Tukey–Kramer test. Analysis of the data for lag phase was performed by the log-rank and Tukey–Kramer tests. **P  <  0.01 (compared with no-seeded); *P  <  0.05 (compared with no-seeded)
Fig. 5
Fig. 5
Seeding activity of insoluble aggregates of r-αSyn induced by incubation. WT or S129A r-αSyn (14 μg) was incubated at 37 °C in the presence (+) or absence (−) of 140 U of casein kinase 2 (CK2) or 200 μM ATP in 35 μl of reaction buffer (20 mM Tris-HCl, pH 7.5, 50 mM KCl, and 10 mM MgCl2). a After 0 (left panel), 72 (central panel), or 264 h (right panel) of incubation, the samples were immunoblotted with polyclonal anti-αSyn antibody D119 and monoclonal anti-pSer129-αSyn antibody. Molecular mass markers are indicated in kilodaltons (kDa) on the left side of each panel. The arrows indicate the top of the stacking gel. b Levels of ThT fluorescence of WT r-αSyn mixed with CK2 in the absence (WTCK2) or presence (WTCK2+ATP) of ATP and S129A r-αSyn mixed with CK2 and ATP (S129ACK2+ATP) were measured after 0, 72, 168, and 264 h of incubation. Data are expressed as means  ±  standard deviation (n  =  4). c WT or S129A r-αSyn incubated with CK2 and ATP for 0 (WT-0 h and S129A-0 h) or 264 h (WT-264 h and S129A-264 h) were subjected to FTIR analysis. d Samples were examined by TEM. Bars, 200 nm. e Seeding activity of WT-0 h, WT-264 h, S129A-0 h, and S129A-264 h samples was evaluated at dilutions of 2 × 10−2 and 2 × 10−4 by RT-QUIC. The colored curves represent the kinetics of ThT fluorescence averaged over three or four replicate wells
Fig. 6
Fig. 6
Seeding activity of r-αSyn oligomers generated by RT-QUIC. a Fibril formation of WT or S129A r-αSyn (12.5 μg) was induced in the presence of only 125 U of CK2 (WTCK2 and S129ACK2) or both 125 U of CK2 and 200 μM ATP (WTCK2+ATP and S129ACK2+ATP) by RT-QUIC without seed. The colored curves represent the kinetics of ThT fluorescence averaged over triplicate wells. b RT-QUIC samples (WTCK2, WTCK2+ATP, S129ACK2, and S129ACK2+ATP) were immunoblotted with polyclonal anti-αSyn antibody D119 and monoclonal anti-pSer129-αSyn antibody. Molecular mass markers are indicated in kilodaltons (kDa) on the left side of each panel. The arrows indicate the top of the stacking gel. c RT-QUIC samples (WTCK2, WTCK2+ATP, S129ACK2, and S129ACK2+ATP) were subjected to FTIR analysis. d Samples were examined by TEM. Bars, 50 nm. e Seeding activity of RT-QUIC samples (WTCK2, WTCK2+ATP, S129ACK2, and S129ACK2+ATP) was evaluated at dilutions from 2 × 10−4 to 2 × 10−8 by subsequent testing by RT-QUIC. The colored curves represent the kinetics of ThT fluorescence averaged over replicate wells (n  =  3 – 6). f The values of maximal fluorescence intensities and lag phase obtained in individual samples after 72-h reaction are plotted on the left and right graphs, respectively. Lag phase was defined as the time required to reach a fluorescence intensity > 120 arbitrary units. The horizontal bars indicate means  ±  standard deviation. The data for maximal fluorescence intensities were analyzed by one-way ANOVA, followed by the Tukey–Kramer test. Analysis of the data for lag phase was performed by the log-rank and the Tukey–Kramer tests. **P  <  0.01 (compared with 2 × 10−4 dilution of WT-mock); *P  <  0.05 (compared with 2 × 10−4 dilution of WT-mock); ##P  <  0.01 (compared with the same dilution of WTCK2+ATP)

Similar articles

Cited by

References

    1. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160–164. doi: 10.1038/ncb748. - DOI - PubMed
    1. Smith WW, Margolis RL, Li X, et al. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci : the official journal of the Society for Neuroscience. 2005;25:5544–5552. doi: 10.1523/JNEUROSCI.0482-05.2005. - DOI - PMC - PubMed
    1. Paleologou KE, Schmid AW, Rospigliosi CC, et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008;283:16895–16905. doi: 10.1074/jbc.M800747200. - DOI - PMC - PubMed
    1. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005;8:657–663. doi: 10.1038/nn1443. - DOI - PubMed
    1. Gorbatyuk OS, Li S, Sullivan LF, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 2008;105:763–768. doi: 10.1073/pnas.0711053105. - DOI - PMC - PubMed